메뉴 건너뛰기




Volumn 5, Issue 2, 2014, Pages 39-47

Targeted immunotherapy for non-small cell lung cancer

Author keywords

Cytotoxic T Lymphocyte Antigen 4; Immunotherapy; Non small cell lung cancer; Programmed death ligands 1; Programmed death 1

Indexed keywords


EID: 84922260552     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i2.39     Document Type: Article
Times cited : (7)

References (65)
  • 5
    • 79953151458 scopus 로고    scopus 로고
    • Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion
    • [PMID: 21436444]
    • Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570 [PMID: 21436444 DOI: 10.1126/science.1203486331/6024/1565]
    • (2011) Science , vol.331 , pp. 1565-1570
    • Schreiber, R.D.1    Old, L.J.2    Smyth, M.J.3
  • 6
    • 80053222721 scopus 로고    scopus 로고
    • Developing effective cancer vaccines
    • [PMID: 21944017]
    • Baxevanis CN, Perez SA, Papamichail M. Developing effective cancer vaccines. Eur J Cancer 2011; 47 Suppl 3: S364-S365 [PMID: 21944017 DOI: 10.1016/S0959-8049(11)70205-2]
    • (2011) Eur J Cancer , vol.47 , pp. S364-S365
    • Baxevanis, C.N.1    Perez, S.A.2    Papamichail, M.3
  • 7
    • 31444439350 scopus 로고    scopus 로고
    • Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma
    • [PMID: 16421594]
    • Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-280 [PMID: 16421594]
    • (2006) Br J Cancer , vol.94 , pp. 275-280
    • Hiraoka, K.1    Miyamoto, M.2    Cho, Y.3    Suzuoki, M.4    Oshikiri, T.5    Nakakubo, Y.6    Itoh, T.7    Ohbuchi, T.8    Kondo, S.9    Katoh, H.10
  • 8
    • 53149083361 scopus 로고    scopus 로고
    • Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer
    • [PMID: 18671239]
    • Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113: 1387-1395 [PMID: 18671239 DOI: 10.1002/cncr.23712]
    • (2008) Cancer , vol.113 , pp. 1387-1395
    • Kawai, O.1    Ishii, G.2    Kubota, K.3    Murata, Y.4    Naito, Y.5    Mizuno, T.6    Aokage, K.7    Saijo, N.8    Nishiwaki, Y.9    Gemma, A.10    Kudoh, S.11    Ochiai, A.12
  • 9
    • 77951877847 scopus 로고    scopus 로고
    • Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer
    • [PMID: 20234320]
    • Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010; 5: 585-590 [PMID: 20234320 DOI: 10.1097/JTO.0b013e3181d60fd7]
    • (2010) J Thorac Oncol , vol.5 , pp. 585-590
    • Shimizu, K.1    Nakata, M.2    Hirami, Y.3    Yukawa, T.4    Maeda, A.5    Tanemoto, K.6
  • 10
    • 84881458660 scopus 로고    scopus 로고
    • Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma
    • [PMID: 23851682]
    • Ganesan AP, Johansson M, Ruffell B, Yagui-Beltrán A, Lau J, Jablons DM, Coussens LM. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol 2013; 191: 2009-2017 [PMID: 23851682 DOI: 10.4049/jimmunol.1301317]
    • (2013) J Immunol , vol.191 , pp. 2009-2017
    • Ganesan, A.P.1    Johansson, M.2    Ruffell, B.3    Yagui-Beltrán, A.4    Lau, J.5    Jablons, D.M.6    Coussens, L.M.7
  • 11
    • 83555173668 scopus 로고    scopus 로고
    • Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways
    • [PMID: 21959954]
    • Yao M, Zhang W, Zhang Q, Xing L, Xu A, Liu Q, Cui B. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways. Lung 2011; 189: 453-460 [PMID: 21959954 DOI: 10.1007/s00408-011-9327-y]
    • (2011) Lung , vol.189 , pp. 453-460
    • Yao, M.1    Zhang, W.2    Zhang, Q.3    Xing, L.4    Xu, A.5    Liu, Q.6    Cui, B.7
  • 12
    • 0034789572 scopus 로고    scopus 로고
    • Phase i study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer
    • discussion 58 [PMID: 14656392]
    • Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, MacLean G, Longenecker M. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001; 3: 49-57; discussion 58 [PMID: 14656392]
    • (2001) Clin Lung Cancer , vol.3 , pp. 49-57
    • Palmer, M.1    Parker, J.2    Modi, S.3    Butts, C.4    Smylie, M.5    Meikle, A.6    Kehoe, M.7    MacLean, G.8    Longenecker, M.9
  • 14
    • 0029787977 scopus 로고    scopus 로고
    • Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
    • [PMID: 8877724]
    • MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996; 19: 309-316 [PMID: 8877724]
    • (1996) J Immunother Emphasis Tumor Immunol , vol.19 , pp. 309-316
    • MacLean, G.D.1    Miles, D.W.2    Rubens, R.D.3    Reddish, M.A.4    Longenecker, B.M.5
  • 15
    • 80054742888 scopus 로고    scopus 로고
    • Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial
    • [PMID: 21744082]
    • Butts C, Maksymiuk A, Goss G, Soulières D, Marshall E, Cormier Y, Ellis PM, Price A, Sawhney R, Beier F, Falk M, Murray N. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011; 137: 1337-1342 [PMID: 21744082 DOI: 10.1007/s00432-011-1003-3]
    • (2011) J Cancer Res Clin Oncol , vol.137 , pp. 1337-1342
    • Butts, C.1    Maksymiuk, A.2    Goss, G.3    Soulières, D.4    Marshall, E.5    Cormier, Y.6    Ellis, P.M.7    Price, A.8    Sawhney, R.9    Beier, F.10    Falk, M.11    Murray, N.12
  • 19
    • 33644912878 scopus 로고    scopus 로고
    • A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells
    • [PMID: 16446550]
    • Miyagawa N, Kono K, Mimura K, Omata H, Sugai H, Fujii H. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. Oncology 2006; 70: 54-62 [PMID: 16446550]
    • (2006) Oncology , vol.70 , pp. 54-62
    • Miyagawa, N.1    Kono, K.2    Mimura, K.3    Omata, H.4    Sugai, H.5    Fujii, H.6
  • 27
    • 18344390418 scopus 로고    scopus 로고
    • ERBB receptors and cancer: The complexity of targeted inhibitors
    • [PMID: 15864276]
    • Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354 [PMID: 15864276]
    • (2005) Nat Rev Cancer , vol.5 , pp. 341-354
    • Hynes, N.E.1    Lane, H.A.2
  • 32
    • 38949193901 scopus 로고    scopus 로고
    • Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine
    • [PMID: 18245547]
    • García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008; 14: 840-846 [PMID: 18245547 DOI: 10.1158/1078-0432.CCR-07-1050]
    • (2008) Clin Cancer Res , vol.14 , pp. 840-846
    • García, B.1    Neninger, E.2    De La Torre, A.3    Leonard, I.4    Martínez, R.5    Viada, C.6    González, G.7    Mazorra, Z.8    Lage, A.9    Crombet, T.10
  • 34
    • 0348223787 scopus 로고    scopus 로고
    • Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3
    • [PMID: 14676299]
    • Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, Mc-Grady G, Wahl SM. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886 [PMID: 14676299 DOI: 10.1084/jem.20030152]
    • (2003) J Exp Med , vol.198 , pp. 1875-1886
    • Chen, W.1    Jin, W.2    Hardegen, N.3    Lei, K.J.4    Li, L.5    Marinos, N.6    Mc-Grady, G.7    Wahl, S.M.8
  • 35
    • 0033229730 scopus 로고    scopus 로고
    • Plasma transforming growth factor-beta1 level before radio-therapy correlates with long term outcome of patients with lung carcinoma
    • [PMID: 10547543]
    • Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radio-therapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999; 86: 1712-1719 [PMID: 10547543]
    • (1999) Cancer , vol.86 , pp. 1712-1719
    • Kong, F.1    Jirtle, R.L.2    Huang, D.H.3    Clough, R.W.4    Anscher, M.S.5
  • 37
    • 67651091694 scopus 로고    scopus 로고
    • Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
    • [PMID: 19287371]
    • Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009; 16: 620-624 [PMID: 19287371 DOI: 10.1038/cgt.2009.15]
    • (2009) Cancer Gene Ther , vol.16 , pp. 620-624
    • Nemunaitis, J.1    Nemunaitis, M.2    Senzer, N.3    Snitz, P.4    Bedell, C.5    Kumar, P.6    Pappen, B.7    Maples, P.B.8    Shawler, D.9    Fakhrai, H.10
  • 40
    • 65349083187 scopus 로고    scopus 로고
    • Negative regulators of T-cell activation: Potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
    • [PMID: 19426215]
    • Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229: 67-87 [PMID: 19426215 DOI: 10.1111/j.1600-065X.2009.00763.x]
    • (2009) Immunol Rev , vol.229 , pp. 67-87
    • Pentcheva-Hoang, T.1    Corse, E.2    Allison, J.P.3
  • 43
    • 55949083407 scopus 로고    scopus 로고
    • Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment
    • [PMID: 18838703]
    • Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275-5283 [PMID: 18838703 DOI: 10.1200/JCO.2008.17.8954]
    • (2008) J Clin Oncol , vol.26 , pp. 5275-5283
    • Fong, L.1    Small, E.J.2
  • 44
    • 84863911486 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study
    • [PMID: 22547592]
    • Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30: 2046-2054 [PMID: 22547592 DOI: 10.1200/JCO.2011.38.4032]
    • (2012) J Clin Oncol , vol.30 , pp. 2046-2054
    • Lynch, T.J.1    Bondarenko, I.2    Luft, A.3    Serwatowski, P.4    Barlesi, F.5    Chacko, R.6    Sebastian, M.7    Neal, J.8    Lu, H.9    Cuillerot, J.M.10    Reck, M.11
  • 45
    • 0033811566 scopus 로고    scopus 로고
    • Paclitaxel (175 mg/m2) plus carboplatin (6 auc) versus paclitaxel (225 mg/m2) plus carboplatin (6 auc) in advanced non-smallcell lung cancer (NSCLC): A multicenter randomized trial hellenic cooperative oncology group (hecog)
    • [PMID: 10997806]
    • Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C, Kalophonos C, Pavlidis N, Nikolaidis C, Papaconstantinou C, Fountzilas G. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-smallcell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000; 11: 799-805 [PMID: 10997806]
    • (2000) Ann Oncol , vol.11 , pp. 799-805
    • Kosmidis, P.1    Mylonakis, N.2    Skarlos, D.3    Samantas, E.4    Dimopoulos, M.5    Papadimitriou, C.6    Kalophonos, C.7    Pavlidis, N.8    Nikolaidis, C.9    Papaconstantinou, C.10    Fountzilas, G.11
  • 47
    • 78449244037 scopus 로고    scopus 로고
    • The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
    • [PMID: 21074065]
    • Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507 [PMID: 21074065 DOI: 10.1053/j.seminoncol.2010.09.007]
    • (2010) Semin Oncol , vol.37 , pp. 499-507
    • Di Giacomo, A.M.1    Biagioli, M.2    Maio, M.3
  • 51
    • 84255197842 scopus 로고    scopus 로고
    • Cancer immunotherapy comes of age
    • [PMID: 22193102]
    • Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489 [PMID: 22193102 DOI: 10.1038/nature10673]
    • (2011) Nature , vol.480 , pp. 480-489
    • Mellman, I.1    Coukos, G.2    Dranoff, G.3
  • 52
    • 78449243489 scopus 로고    scopus 로고
    • Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade
    • [PMID: 21074057]
    • Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37: 430-439 [PMID: 21074057 DOI: 10.1053/j.seminoncol.2010.09.005]
    • (2010) Semin Oncol , vol.37 , pp. 430-439
    • Weber, J.1
  • 61
    • 84904856935 scopus 로고    scopus 로고
    • Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC)
    • Garon Eea, Balmanoukian A, Hamid O. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). IASLC 15th World Conference on Lung Cancer. Sydney, 2013
    • (2013) IASLC 15th World Conference on Lung Cancer. Sydney
    • Garon Eea1    Balmanoukian, A.2    Hamid, O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.